SavedAdd your journal

Journals / Çukurova Anestezi ve Cerrahi Bilimler Dergisi / 2021 / Cilt: 4 - Sayı: 1

PROPHYLACTIC SURGERY IN LYNCH SYNDROME: WHEN AND HOW? UPDATE AND LITERATURE REVIEW

LYNCH SENDROMUNDA PROFİLAKTİK CERRAHİ: NE ZAMAN VE NASIL? GÜNCEL YAKLAŞIMLAR VE LİTERATÜR DERLEMESİ

Emrah Akin
Uğur Dülger
Fatih Altintoprak
Pages
37–44
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Surveillance studies should be started in individuals at risk of Lynch Syndrome from the age of 20, it should be continued annually in mutation positive carriers and prophylactic surgery should also be included in the presence of certain conditions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lynch syndrome; It is an autosomal dominant inherited cancer predisposing syndrome, characterized by solitary adenomas and extra- colonic manifestations transforming into colorectal cancer.
📊
Key Findings & Data:The diagnosis of the syndrome could made by clinical findings, pathological features, family history and genetic tests.
💡
Conclusion & Impact:Surveillance studies should be started in individuals at risk of Lynch Syndrome from the age of 20, it should be continued annually in mutation positive carriers and prophylactic surgery should also be included in the presence of certain conditions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lynch syndrome; It is an autosomal dominant inherited cancer predisposing syndrome, characterized by solitary adenomas and extra- colonic manifestations transforming into colorectal cancer. The diagnosis of the syndrome could made by clinical findings, pathological features, family history and genetic tests. Surveillance studies should be started in individuals at risk of Lynch Syndrome from the age of 20, it should be continued annually in mutation positive carriers and prophylactic surgery should also be included in the presence of certain conditions.

Özet

Lynch sendromu; kolorektal kansere dönüşen soliter adenomlar ve ekstra-kolonik manifestasyonlarla karakterize, otozomal dominant kalıtımlı bir kanser predispozan sendromdur. Sendromun tanısı klinik bulgular, patolojik özellikler, aile öyküsü ve genetik testler ile koyulabilir. Lynch Sendromu riski altında olan bireylerde tarama çalışmalarına 20’ li yaşlardan itibaren başlanmalı, mutasyon pozitif taşıyıcılarında yıllık olarak devam edilmeli ve belli şartların varlığında da profilaktik cerrahi gündeme alınmalıdır.

🔖

Cite This Article

Akin, E., Dülger, U., Altintoprak, F. (2022). PROPHYLACTIC SURGERY IN LYNCH SYNDROME: WHEN AND HOW? UPDATE AND LITERATURE REVIEW. Çukurova Anestezi ve Cerrahi Bilimler Dergisi, Cilt: 4 - Sayı: 1, 37–44. https://ajindex.com/articles/484598

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Boland CR, Lynch HT. The history of Lynch syndrome. Fam Cancer. 2013;12(2):145-57.
  2. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66(3):589–600. https://doi.org/ 10.1016/0092-8674(81)90021-0 3. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015;15(3):181-94.
  3. Salovaara R, Loukola A, Kristo P, et al. Population-based moleculardetection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193–200
  4. Jass J, Stewart S, Stewart J, Lane MR. Hereditary non-polyposis colorectal cancer-- morphologies, genes and mutations. Mutat Res. 1994;310(1):125–33.
  5. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919-32.
  6. Win AK, Young JP, Lindor NM, Tucker MK, Ahnen DJ, Young GP,et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012;30(9):958-64.
  7. Guillem JG, Smith AJ, Calle JP, et al. Gastrointestinal polyposis syndromes. Curr Probl Surg. 1999;36(4):217-323.
  8. Goodenberger ML, Thomas BC, Riegert- Johnson D, Boland CR, Plon SE, Clendenning M, et al. PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016;18(1):13-9. https://doi.org/11.1038/gim.2015.27 10. de Rosa N, Rodriguez-Bigas MA, Chang GJ, et al. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol. 2016;34(25):3039-46.
  9. Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol 2014;12(5):715-27; quiz e41-3.
  10. Brixen LM, Bernstein IT, Bulow S, et al. Survival of patients with Stage III colon cancer is improved in hereditary non-polyposis colorectal cancer compared with sporadic cases. A Danish registry based study. Colorectal Dis. 2013;15(7):816-23.
  11. Yang Y, Nancy